A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

NCT02754817 · Completed

Last updated 2026-05-28

This study tested the effects of the medication Xultophy® (a combination of insulin degludec and liraglutide) on adults with type 2 diabetes in real-world settings.

Status Completed The study has finished.

Type Observational

Participants 611 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-04 · est. completion 2016-10

Where 5 sites · Austria, Germany, Sweden, Switzerland, United Kingdom

What this study is testing ClinicalTrials.gov NCT02754817 ↗

Description as written by the study sponsor.

This study is conducted in Europe. The aim of the study is to investigate the effectiveness of Xultophy® (insulin degludec/liraglutide) in an adult real-world population with type 2 diabetes mellitus.

Treatments tested

insulin degludec/liraglutide Drug

This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.

Main thing measured	Change in HbA1c (Hemoglobin A1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02754817 ↗